NASDAQ:BIS ProShares UltraShort Nasdaq Biotechnology (BIS) Price, Holdings, & News $13.95 -0.67 (-4.58%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$13.96 +0.01 (+0.04%) As of 06/26/2026 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIS alerts:Sign Up Key Stats Today's Range$13.81▼$14.2550-Day Range$13.95▼$18.3152-Week Range$13.81▼$35.59Volume8,047 shsAverage Volume8,042 shsMarket Capitalization$1.95 millionAssets Under ManagementN/ADividend Yield7.17%Net Expense Ratio0.95%Aggregate RatingN/A ETF Overview ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund. Read More ProShares UltraShort Nasdaq Biotechnology ExpensesTypeBISHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.56%0.57%0.54%0.53%Other Expenses1.67%0.47%0.55%0.51%0.55%Total Expense2.42%0.74%0.76%0.73%0.73%Fee Waiver-1.47%-0.71%-0.64%-0.50%-0.62%Net Expense0.95%0.59%0.63%0.62%0.60% Receive BIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraShort Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIS ETF News HeadlinesUltrashort NASDAQ Biotechnology declares quarterly distribution of $0.1366June 24 at 7:47 PM | msn.comProShares UltraShort Nasdaq BiotechMay 28, 2026 | money.usnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.June 27 at 1:00 AM | Weiss Ratings (Ad)UltraShort NASDAQ Biotechnology declares quarterly distribution of $0.0686March 25, 2026 | msn.comRetail traders using leveraged ETFs were a major driver of January's dramatic gold and silver selloff – BISMarch 17, 2026 | kitco.comKUltrashort NASDAQ Biotechnology declares quarterly distribution of $0.1025December 24, 2025 | msn.comSee More Headlines BIS ETF - Frequently Asked Questions How have BIS shares performed this year? ProShares UltraShort Nasdaq Biotechnology's stock was trading at $18.96 on January 1st, 2026. Since then, BIS shares have decreased by 26.4% and is now trading at $13.95. When did ProShares UltraShort Nasdaq Biotechnology's stock split? ProShares UltraShort Nasdaq Biotechnology shares reverse split on Tuesday, August 18th 2020.The 1-4 reverse split was announced on Tuesday, August 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 17th 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of ProShares UltraShort Nasdaq Biotechnology? Shares of BIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProShares UltraShort Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraShort Nasdaq Biotechnology investors own include Micron Technology (MU), Inovio Pharmaceuticals (INO), Sanofi (SNY), Intel (INTC), Meta Platforms (META), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Fund Details IssuerProShares Fund NameProShares UltraShort Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:BIS Inception Date4/7/2010 Fund ManagerMichael Neches, Tarak Dave Webwww.proshares.com Phone+1-240-4976400Fund Focus Asset ClassEquity BenchmarkNasdaq Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings28 Fund Statistics Assets Under Management$0.00 Average Daily Volume$6.70 thousand Discount/Premium0.00% Leveraged-2.00 Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors, LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest4,200 shs Miscellaneous Outstanding Shares140,000Beta-1.22 Creation Unit50,000 Creation Fee$250.00 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report Top 6 BIS HoldingsNET OTHER ASSETS (LIABILITIES)Holding Weight: 0.00%NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEHolding Weight: -31.60%NASDAQ BIO INDEX SWAP BNP PARIBASHolding Weight: -33.60%NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGHolding Weight: -34.94%NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAHolding Weight: -35.61%NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAHolding Weight: -64.76%Full Holdings Details This page (NASDAQ:BIS) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraShort Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares UltraShort Nasdaq Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIS Stock Alerts